scholarly journals Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors

2015 ◽  
Vol 21 (12) ◽  
pp. 2115-2122 ◽  
Author(s):  
Jennifer A. Kanakry ◽  
Christopher D. Gocke ◽  
Javier Bolaños-Meade ◽  
Douglas E. Gladstone ◽  
Lode J. Swinnen ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
B Cell ◽  
Marrow Transplantation ◽  
Phase Ii Study ◽  
Cell Lymphoma ◽  
Allogeneic Bone Marrow Transplantation ◽  
B Cell Lymphoma ◽  
Allogeneic Bone ◽  
Post Transplantation

scholarly journals EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation

Blood ◽  
2018 ◽  
Vol 132 (22) ◽  
pp. 2351-2361 ◽  
Author(s):  
Lauren P. McLaughlin ◽  
Rayne Rouce ◽  
Stephen Gottschalk ◽  
Vicky Torrano ◽  
George Carrum ◽  
...  
Keyword(s):  
Bone Marrow ◽  
T Cells ◽  
Bone Marrow Transplantation ◽  
B Cell ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone

Abstract There is a Blood Commentary on this article in this issue.

Hepatosplenic γδ T-cell lymphoma after allogeneic bone marrow transplantation

2015 ◽  
Vol 94 (6) ◽  
pp. 1077-1078 ◽  
Author(s):  
Marie-Christiane Vekemans ◽  
Lucienne Michaux ◽  
Pascale Saussoy ◽  
Eric Van Den Neste ◽  
Ivan Théate ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
T Cell ◽  
Marrow Transplantation ◽  
Cell Lymphoma ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
T Cell Lymphoma ◽  
Allogeneic Bone ◽  
Γδ T Cell

Marginal zone B-cell lymphoma arising in donor cells in a Hepatitis-C virus infected patient over 20 years after allogeneic bone marrow transplantation

2008 ◽  
Vol 49 (11) ◽  
pp. 2219-2221
Author(s):  
Francesca Zaccheddu ◽  
Angela Maria Mamusa ◽  
Maria Giuseppina Cabras ◽  
Fabio Culurgioni ◽  
Martina Pettinau ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Hepatitis C ◽  
Bone Marrow Transplantation ◽  
Infected Patient ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
Allogeneic Bone Marrow Transplantation ◽  
B Cell Lymphoma ◽  
Allogeneic Bone ◽  
Donor Cells

scholarly journals Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation

Lupus ◽  
2016 ◽  
Vol 26 (7) ◽  
pp. 773-776 ◽  
Author(s):  
D E Gladstone ◽  
M Petri ◽  
J Bolaños-Meade ◽  
A E Dezern ◽  
R J Jones ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Lupus Erythematosus ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Systemic Lupus ◽  
Post Transplantation

Systemic lupus erythematosus (SLE), a disorder of the immune system, is potentially curable by allogeneic bone marrow transplantation (alloBMT). Until recently, alloBMT was limited by donor availability and toxicity. Reduced intensity conditioning (RIC) combined with post-transplantation cyclophosphamide (PTCy) has improved the availability and safety of alloBMT permitting its exploration in severe-refractory autoimmune illnesses. We report the six-year follow-up of a young female whose refractory SLE-associated nephrosis resolved after RIC alloBMT with PTCy.

Sign in / Sign up

Export Citation Format

Share Document